About the Authors
- Yijung Yang
-
Affiliation Laboratory of Neurobiology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
- Jung-Hwa Tao-Cheng
-
Affiliation EM Facility, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
- K. Ulrich Bayer
-
Affiliation Department of Pharmacology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States of America
- Thomas S. Reese
-
Affiliation Laboratory of Neurobiology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
- Ayse Dosemeci
-
* E-mail: dosemeca@mail.nih.gov
Affiliation Laboratory of Neurobiology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
Competing Interests
The University of Colorado is currently seeking patent protection for tatCN21, its derivatives, and its uses (PCT/US08/077934 “Compositions and methods for improved CaMKII inhibitors and uses thereof”). This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AD YY JHTC. Performed the experiments: YY JHTC. Analyzed the data: AD YY JHTC. Contributed reagents/materials/analysis tools: KUB. Wrote the paper: YY JHTC KUB TR AD.